CLINICAL TRIALS PROFILE FOR ACTIVELLA

All Clinical Trials for Activella

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00919919 ↗	Efficacy and Tolerability Study of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen	Unknown status	Ferring Pharmaceuticals	Phase 2	2009-06-01	The objective of the study is to confirm that the efficacy of vaginal progesterone is at least as good as oral progesterone in order to protect the endometrium of uncontrolled proliferation and prevent endometrial cancer.
NCT00919919 ↗	Efficacy and Tolerability Study of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen	Unknown status	Rabin Medical Center	Phase 2	2009-06-01	The objective of the study is to confirm that the efficacy of vaginal progesterone is at least as good as oral progesterone in order to protect the endometrium of uncontrolled proliferation and prevent endometrial cancer.
NCT01157182 ↗	Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fasting Conditions	Completed	Teva Pharmaceuticals USA	Phase 1	2007-02-01	The objective of this study was to determine and compare the rate and extent of absorption of norethindrone and unconjugated estradiol from a test formulation of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg versus the reference Activella® (1 mg estradiol/0.5 mg norethindrone acetate) Tablets under fasting conditions.
NCT01181726 ↗	Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fed Conditions	Completed	Teva Pharmaceuticals USA	Phase 1	2007-01-01	The objective of this study was to determine and compare the rate and extent of absorption of norethindrone and unconjugated estradiol from a test formulation of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg versus the reference Activella® (1 mg estradiol/0.5 mg norethindrone acetate) Tablets under fed conditions.
NCT01817530 ↗	Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)	Completed	AbbVie	Phase 2	2013-04-08	This is a Phase 2b randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of elagolix alone and in combination with add-back therapy versus placebo on heavy menstrual bleeding in premenopausal women 18 to 51 years of age with uterine fibroids.
NCT02693002 ↗	Estrogen Diastolic Heart Failure	Terminated	Gretchen Wells	Phase 4	2016-02-01	Peri-menopausal women will be randomized to hormone replacement therapy or placebo for 12 weeks to determine if markers of systolic and diastolic function change by echocardiography as well as laboratory markers of heart failure, including b-type natriuretic peptide (BNP).

Clinical Trial Conditions for Activella

Condition Name

Condition Name for Activella
Intervention	Trials
Healthy	2
Heavy Uterine Bleeding	1
Menopause	1
Uterine Fibroids	1

Condition MeSH

Condition MeSH for Activella
Intervention	Trials
Hemorrhage	1
Endometriosis	1
Hyperplasia	1
Heart Failure	1

Clinical Trial Locations for Activella

Trials by Country

Trials by Country for Activella
Location	Trials
United States	66
Canada	5
Puerto Rico	2
United Kingdom	1
Israel	1

Trials by US State

Trials by US State for Activella
Location	Trials
Kentucky	3
New Jersey	2
Michigan	2
Louisiana	2
Indiana	2

Clinical Trial Progress for Activella

Clinical Trial Phase

Clinical Trial Phase for Activella
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
Phase 2	2

Clinical Trial Status

Clinical Trial Status for Activella
Clinical Trial Phase	Trials
Completed	3
Terminated	1
Unknown status	1

Clinical Trial Sponsors for Activella

Sponsor Name

Sponsor Name for Activella
Sponsor	Trials
Teva Pharmaceuticals USA	2
AbbVie	2
Ferring Pharmaceuticals	1

Sponsor Type

Sponsor Type for Activella
Sponsor	Trials
Industry	5
Other	2